Biochemical markers of bone metabolism in multiple myeloma

Cancer Treatment Reviews

Volumn 32, Issue SUPPL. 1, 2006, Pages 15-19

  Terpos, Evangelos ^a  

^a General Airforce Hospital   (Greece)

Author keywords

BAP; Bone resorption markers; ICTP; Multiple myeloma; NTX; sRANKL OPG; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; DEXAMETHASONE; FRIZZLED PROTEIN; IBANDRONIC ACID; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; SIALOPROTEIN; THALIDOMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; BONE MARROW TRANSPLANTATION; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; FOLLOW UP; FRACTURE; FRACTURE HEALING; HUMAN; MEDICAL ASSESSMENT; MULTIPLE MYELOMA; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PROGNOSIS; TREATMENT OUTCOME;

BONE AND BONES; HUMANS; MULTIPLE MYELOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 33646239372     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(06)80004-6     Document Type: Article

References (42)

1. Available at:. Cancer Research UK. Accessed October 5, 2005. Cancer Stats: Incidence-UK (March 2005). http://www.cancerresearchuk.org/aboutcancer/statistics/statsmisc/pdfs/cancerstats_incidence_apr05.pdf
2. Corso A., Arcaini L., Mangiacavalli S., et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma: a study on their role in identifying high risk patients. Haematologica 86 (2001) 394-398
3. Coleman R. Bisphosphonates: clinical experience. Oncologist 9 Suppl 4 (2004) 14-27
4. Ibrahim A., Scher N., Williams G., et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 9 (2003) 2394-2399
5. Roodman G. Biology of osteoclast activation in cancer. J Clin Oncol 20 (2001) 353-354
6. Anderson K., Shaughnessy Jr. J., Barlogie B., Harousseau J., and Roodman G. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) (2002) 214-240
7. Jakob C., Zavrski I., Heider U., et al. Bone resorption parameters [carboxy-terminal telopeptide of collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 69 (2002) 37-42
8. Terpos E., Politou M., and Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev 19 (2005) 125-142
9. Halleen J., Ylipahkala H., Alatalo S., et al. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71 (2002) 20-25
10. Halleen J., Alatalo S., Suominen H., Cheng S., Janckila A., and Vaananen H. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15 (2000) 1337-1345
11. Halleen J., Alatalo S., Janckila A., Woitge H., Seibel M., and Vaananen H. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47 (2001) 597-600
12. Withold W., Arning M., Schwarz M., Wolf H., and Schneider W. Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation. Clin Chim Acta 269 (1998) 21-30
13. Carlson K., Larsson A., Simonsson B., Turesson I., Westin J., and Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 62 (1999) 300-306
14. Fonseca R., Trendle M., Leong T., et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 109 (2000) 24-29
15. Terpos E., Szydlo R., Apperley J., et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
16. Abildgaard N., Bentzen S., Nielsen J., and Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Br J Haematol 96 (1997) 103-110
17. Coleman R., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
18. Seidel C., Hjertner O., Abildgaard N., et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98 (2001) 2269-2271
19. Zangari M., Esseltine D., Lee C., et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131 (2005) 71-73
20. Terpos E., Politou M., Szydlo R., et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 18 (2004) 1420-1426
21. Abildgaard N., Brixen K., Kristensen J., Eriksen E., Nielsen J., and Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-NLx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 120 (2003) 235-242
22. Abildgaard N., Brixen K., Eriksen E., Kristensen J., Nielsen J., and Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 89 (2004) 567-577
23. Alexandrakis M., Passam F., Malliaraki N., Katachanakis C., Kyriakou D., and Margioris A. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 325 (2002) 51-57
24. Elomaa I., Virkkunen P., Risteli L., and Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66 (1992) 337-341
25. Elomaa I., Risteli L., Laakso M., Lahtinen R., Virkkunen P., and Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer 32A (1996) 1166-1170
26. Woitge H., Pecherstorfer M., Li Y., et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14 (1999) 792-801
27. Abildgaard N., Glerup H., Rungby J., et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 64 (2000) 121-129
28. Houze P., Bellik B., Brouet J., Bouro F., and Bousquet B. Comparison of urinary markers for bone resorption in multiple myeloma. Clin Chim Acta 300 (2000) 181-193
29. Terpos E., de la Fuente J., Szydlo R., et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 106 (2003) 455-457
30. Politou M., Terpos E., Anagnostopoulos A., et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 126 (2004) 686-689
31. Woitge H., Pecherstorfer M., Horn E., et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84 (2001) 344-351
32. Woitge H., Horn E., Keck A., Auler B., Seiber M., and Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 47 (2001) 686-693
33. Terpos E., Viniou N., de la Fuente J., et al. Pamidronate is superior to ibandromate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 70 (2003) 34-42
34. Terpos E., Palermos J., Tsionos K., et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 65 (2000) 331-336
35. Terpos E., Palermos J., Viniou N., Vaiopoulos G., Meletis J., and Yataganas X. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment. Calcif Tissue Int 68 (2001) 285-290
36. Terpos E., Mihou D., Szydlo R., et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 19 (2005) 1969-1976
37. Shimazaki C., Uchida R., Nakano S., et al. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 16 (2005) 1102-1103
38. Clark R., Flory A., Ion E., Woodcock B., Durham B., and Fraser W. Biochemical markers of bone turnover following highdose chemotherapy and autografting in multiple myeloma. Blood 96 (2000) 2697-2702
39. Lipton A., Ali S., Leitzel K., et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8 (2002) 2306-2310
40. Body J., Greipp P., Coleman R., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 3 Suppl (2003) 887-892
41. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2483-2494
42. Oshima T., Abe M., Asano J., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106 (2005) 3160-3165